blinatumomab (Blincyto)
Jump to navigation
Jump to search
Indications
- precursor B-cell acute lymphoblastic leukemia[1]
- Philadelphia chromosome-positive or negative[2]
- relapsed or refractory disease
- patients with minimal residual disease[2]
Adverse effects
- fever, febrile neutropenia
- headache
- peripheral edema
- nausea
- hypokalaemia
- fatigue
- constipation
- diarrhea
- tremor
- cytokine release syndrome
- encephalopathy
Mechanism of action
- bispecific antibody
- links CD19 on the surface of B-cell lymphoblasts with CD3 on T-cell lymphocytes
More general terms
References
- ↑ 1.0 1.1 FDA News Release. December 3, 2014. FDA approves Blincyto to treat a rare form of acute lymphoblastic leukemia. First anti-CD19 drug to receive agency approval. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425549.htm
- ↑ 2.0 2.1 2.2 Ingram I. Blincyto OK'd for MRD-Positive Acute Lymphoblastic Leukemia. Residual disease undetectable in 70 of 86 patients treated. MedPage Today. March 29, 2018 https://www.medpagetoday.com/hematologyoncology/leukemia/72073
FDA News Release. March 29, 2018 FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm603151.htm - ↑ Brown PA, Ji L, Xu X et al Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents,and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia. A Randomized Clinical Trial. JAMA. 2021;325(9):833-842 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33651090 https://jamanetwork.com/journals/jama/fullarticle/2776879
Locatelli F, Zugmaier G, Rizzari C et al Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. A Randomized Clinical Trial. JAMA. 2021;325(9):843-854. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33651091 https://jamanetwork.com/journals/jama/fullarticle/2776881
Shukla N, Sulis ML Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia. JAMA. 2021;325(9):830-832 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33651075 https://jamanetwork.com/journals/jama/fullarticle/2776860 - ↑ Kinnaman M Blinatumomab a Game Changer for B-cell Precursor ALL. Bispecific antibody constructs often compared with CAR T cells. MedPage Today. ASCO Reading Room. April 9, 2021 https://www.medpagetoday.com/reading-room/asco/immunotherapy/91982
Lussan F, Gritti G, Rambaldi A et al Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell- Redirected Bispecific Antibodies. J Clin Oncol 2021. 39(5):444-455. Feb 10. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33434063 https://ascopubs.org/doi/10.1200/JCO.20.01564